BioSpace News Archive

bit.bio, a synthetic biology company working on developing and providing every human cell type at scale, with the aim of transforming the research and medicine landscape, launch their ioGlutamatergic Neurons HTT50CAG/WT cells to advance research and accelerate drug discovery for Huntington’s disease.

RaySearch Laboratories AB is proud to announce an agreement to collaborate with GE Healthcare, a leading global medical technology, diagnostics, and digital solutions company, to develop a new radiation therapy simulation and treatment planning workflow solution, designed to make use of the latest advancements in treatment planning technology.

Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today reported that the first patient has been dosed in a Phase 2a study evaluating tegoprubart in patients with IgA Nephropathy (IgAN).

Lipocine Inc. today announced financial results for the quarter ended March 31, 2022 and provided a corporate update.

LogicBio® Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the company’s LB-001 Investigational New Drug Application (IND), allowing patient enrollment to resume in the Phase 1/2 SUNRISE trial for pediatric patients with methylmalonic acidemia.

Delfi Diagnostics, a pioneering developer of next generation high performance, affordable liquid biopsy tests for early cancer detection, has enrolled the first participants in the CASCADE-LUNG study.

Twist Bioscience Corporation today announced it has entered into a research collaboration and exclusive option license agreement with Astellas Pharma Inc.

Genprex, Inc. today announced that its Chief Medical Officer, Mark Berger, M.D., will be featured as an expert panelist at the 33rd Annual Cancer Progress Conference, taking place virtually May 10-12, 2022.

VBI Vaccines Inc. today announced financial results for the first quarter ending March 31, 2022 and provided a corporate update.

The rising cases of cardiovascular disorders among a considerable chunk of the global populace coupled with rising hospitalization may prove to be a growth accelerator for the cardiovascular information system market during the forecast period of 2021-2031.